Hepatocellular carcinoma in Central Europe: prognostic features and survival
M Schöniger-Hekele, C Müller, M Kutilek, C Oesterreicher, P Ferenci, A Gangl, M Schöniger-Hekele, C Müller, M Kutilek, C Oesterreicher, P Ferenci, A Gangl
Abstract
Background and aims: We investigated the influence of baseline characteristics of patients with hepatocellular carcinoma (HCC) on prognosis and developed a multivariate Cox model predicting survival. All patients were from Central Europe.
Methods: All 245 patients seen at the Department of Gastroenterology and Hepatology at the University of Vienna, Austria, from July 1991 to March 1998 were included in this retrospective study. Nineteen different clinical characteristics and survival time from date of diagnosis were noted. Factors determining survival time were analysed by univariate and multivariate analysis using Cox proportional hazard regression models and a new classification model was constructed. The validity of this model was tested on an independent group of 89 patients, seen from April 1998 to September 1999.
Results: Median survival in patients with HCC was 8.0 months. In a multivariate analysis bilirubin (>2 mg/dl), portal vein thrombosis, prothrombin time (<70%), alpha fetoprotein (>180 microg/l), tumour mass >50%, and enlarged lymph nodes were independent predictors of survival. A newly constructed Cox proportional hazard model (Vienna survival model for HCC=VISUM-HCC) identified three disease stages with different durations of survival (median survival stage 1, 15.2 months; stage 2, 7.2 months; and stage 3, 2.6 months; p=0.00001). Applying the VISUM-HCC survival model to patients in Okuda stage 2 identified subgroups with an excellent and very poor prognosis for which different treatment modalities should be offered.
Conclusions: Our patients with HCC had a poor median survival of eight months. Six easily measurable clinical variables were significant predictors of survival in patients with HCC. The new VISUM-HCC survival model may be useful for stratifying patients with HCC for various clinical treatment modalities.
Figures
References
- Gastroenterology. 1972 Sep;63(3):482-5
- Semin Liver Dis. 1999;19(3):329-38
- Hepatology. 1987 Jan-Feb;7(1):122-8
- Hepatology. 1987 Nov-Dec;7(6):1346-58
- Ann Intern Med. 1988 Mar;108(3):390-401
- Cancer Res. 1988 Dec 15;48(24 Pt 1):7314-8
- Cancer. 1989 Oct 15;64(8):1700-7
- Hepatology. 1990 Oct;12(4 Pt 1):753-60
- World J Surg. 1991 Mar-Apr;15(2):270-85
- Radiology. 1991 Aug;180(2):319-22
- Dig Dis Sci. 1991 Jul;36(7):962-72
- Hepatology. 1991 Aug;14(2):262-8
- N Engl J Med. 1991 Sep 5;325(10):675-80
- Ann Surg. 1991 Sep;214(3):221-8; discussion 228-9
- Am J Surg. 1992 Apr;163(4):387-94
- Hepatology. 1992 Jul;16(1):112-7
- Lancet. 1992 Aug 1;340(8814):285-8
- Hepatology. 1993 Jan;17(1):20-9
- Cancer. 1993 Dec 1;72(11):3202-9
- Gastroenterology. 1994 Mar;106(3):720-7
- Age Ageing. 1994 Jan;23(1):22-7
- Cancer. 1996 Jun 1;77(11):2217-22
- Hepatology. 1997 Feb;25(2):259-62
- Cancer Res. 1997 Aug 15;57(16):3471-7
- Cancer. 1954 May;7(3):462-503
- J Hepatol. 1997 Oct;27(4):756-65
- J Natl Cancer Inst. 1997 Dec 17;89(24):1844-51
- Z Gastroenterol. 1997 Dec;35(12):1059-67
- Digestion. 1998 Aug;59(5):556-62
- Am J Clin Oncol. 1998 Aug;21(4):386-91
- Ann Intern Med. 1998 Oct 15;129(8):643-53
- J Hepatol. 1998 Dec;29(6):944-52
- N Engl J Med. 1999 Mar 11;340(10):745-50
- J Hepatol. 1999 Jul;31(1):133-41
- Cancer. 1985 Aug 15;56(4):918-28
Source: PubMed